Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on January 27, 2005, to report its financial results for the fourth quarter and full year of 2004. The filing itself primarily serves as a notification of the release of this financial information and does not contain the detailed results within the 8-K document itself. Investors are directed to the furnished press release (Exhibit 99.1) and supplemental information on the company's website (Exhibit 99.2) for the actual financial data and operational performance details.
Key Highlights
- 1BMY filed an 8-K on January 27, 2005, to announce financial results.
- 2The report covers the fourth quarter and full year of 2004.
- 3The press release containing detailed financial results is filed as Exhibit 99.1.
- 4Additional supplemental information is available on the company's website as Exhibit 99.2.
- 5This 8-K serves as a notification and incorporation by reference of financial performance data.
- 6Investors need to review the referenced exhibits for a comprehensive understanding of BMY's financial condition and operational results for 2004.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially announce and provide access to Bristol-Myers Squibb's financial results for the fourth quarter and the full year of 2004.
The detailed financial results are not included directly in the 8-K document. Investors should refer to Exhibit 99.1 (the press release dated January 27, 2005) and Exhibit 99.2 (supplemental information from the company's website) which are furnished and incorporated by reference in this filing.
No, this 8-K filing itself does not contain specific financial figures. It acts as a notification mechanism and directs investors to the accompanying press release and supplemental information where these figures are detailed.
The 8-K report was signed by Sandra Leung, Vice President and Secretary, on behalf of Bristol-Myers Squibb Company.